LAURUSLABS vs ONESOURCE: Stock Comparison
LAURUS LABS is the larger company by market capitalisation. LAURUS LABS shows a higher ROE, a higher dividend yield and faster revenue growth, while ONESOURCE SPECL PHARMA L shows a lower P/E and lower leverage. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
LAURUSLABS leads 9; ONESOURCE leads 4 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | LAURUSLABS | ONESOURCE |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | LAURUSLABS | ONESOURCE |
|---|---|---|
| Live Price | ₹2,246.6 | ₹1,574.8 |
| Day Change | 0.12% | 0.33% |
| Volume | 51,202 | 30 |
| 52-Week High | ₹2,244 | ₹1,925 |
| 52-Week Low | ₹917.95 | ₹1,057 |
| Distance from 52W High | 0.12% | -18.19% |
Valuation
| Metric | LAURUSLABS | ONESOURCE |
|---|---|---|
| Market Cap | ₹1.21 L Cr | ₹17,971 Cr |
| P/E Ratio | 110.86x | 0x |
| P/B Ratio | 22.87x | 3.08x |
| EPS | ₹6.8 | ₹2.18 |
| Book Value | ₹100.53 | ₹508.64 |
| Dividend Yield | 0.09% | 0% |
Growth
| Metric | LAURUSLABS | ONESOURCE |
|---|---|---|
| Revenue Growth (TTM YoY) | 5.3% | 0.5% |
| EPS Growth (TTM YoY) | 19.4% | -95.3% |
| Qtr Sales Growth | 11.85% | 4.86% |
| Qtr Profit Growth | 28.35% | 443.77% |
Profitability & Leverage
| Metric | LAURUSLABS | ONESOURCE |
|---|---|---|
| ROE | 16.39% | -1.27% |
| ROCE | 13.68% | 0.43% |
| Net Margin | 13.76% | -5.19% |
| Operating Margin | 19.85% | 2.13% |
| Debt to Equity | 0.44x | 0.22x |
Shareholding
As of Sep 2026 • change vs previous quarter| Metric | LAURUSLABS | ONESOURCE |
|---|---|---|
| Promoter Holding | 27.47% | 30.47%▼ 0.01 pp |
| FII Holding | 30.84%▲ 2.84 pp | 19.46%▲ 0.27 pp |
| DII Holding | 11.86%▼ 1.88 pp | 24.21%▲ 0.83 pp |
| Public Holding | 29.83%▼ 0.95 pp | 25.86%▼ 1.08 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: LAURUS LABS and ONESOURCE SPECL PHARMA L.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.